InvestorsHub Logo
Followers 27
Posts 3416
Boards Moderated 0
Alias Born 07/17/2006

Re: None

Friday, 10/09/2015 2:30:53 PM

Friday, October 09, 2015 2:30:53 PM

Post# of 346053
I wonder what percentage of NSCLC patients treated with Opdivo enjoyed double the survival period of the SOC. I wonder how many more Opdivo NSCLC patients would have survived as long with Bavi in the mix.

I guess we'll just have to wait for the Sunrise trial and the new Bavi-Opdivo trials to find out.

GLTA, Especially Bavi-arm Sunrise Patients,

Paul
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News